Show simple item record

dc.contributor.authorRizzo, Maria Candida Faria Varanda [UNIFESP]
dc.contributor.authorSolé, Dirceu [UNIFESP]
dc.contributor.authorNaspitz, Charles Kirov [UNIFESP]
dc.date.accessioned2018-06-15T12:52:59Z
dc.date.available2018-06-15T12:52:59Z
dc.date.issued2007-09-01
dc.identifierhttp://dx.doi.org/10.1157/13110315
dc.identifier.citationAllergologia Et Immunopathologia. Barcelona: Elsevier Doyma Sl, v. 35, n. 5, p. 197-208, 2007.
dc.identifier.issn0301-0546
dc.identifier.urihttp://repositorio.unifesp.br/11600/42193
dc.description.abstractBackground: Topical administration of Corticosteroids (CS) can reduce the total dose of CS required to treat the patient and minimize side effects. Topical CS is extremely effective and has an excellent safety profile. Nonetheless, care must be taken when multiple sites such as lungs, nose and skin are being treated. CS mechanisms of action on the inflammatory process are complex. The aim of this study is to review such mechanisms and the adverse events secondary to it.Methods: Review English database (Embase, Pub-Med, Scielo) searching words: CS, adverse events, inhaled CS, intranasal CS, and children.Results: There is a classic mechanism involving a genomic effect of CS and a non-genomic effect, independently of gene transcription process. This mechanism acts by reducing mucosal blood flow in the asthmatic airways. Second-generation topical CS is the treatment of choice in allergic diseases control because of their good anti-inflammatory activity, poor absorption and first-pass hepatic metabolism. When comparing different CS, it is important to compare therapeutically equivalent doses. Although topical CS reduces systemic side effects, local and even systemic side effects can occur. Many factors affect the amount of drug that reaches the lung, including inhaler technique and inhaler type, fine particle dose and particle distribution.Conclusion: Most patients with allergic diseases respond to CS treatment, but there is a small subset of them whose response is unsatisfactory even with high doses of CS. They are classified as corticosteroid-resistant asthmatics. Pro-inflammatory cytokines appear to up regulate the expression of GR beta that has been associated with CS resistance.en
dc.format.extent197-208
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofAllergologia Et Immunopathologia
dc.rightsAcesso restrito
dc.subjectcorticosteroidsen
dc.subjectinhaled corticosteroidsen
dc.subjectsteroidsen
dc.subjectasthmaen
dc.subjectrhinitisen
dc.subjectChildrenen
dc.subjectbioavailabilityen
dc.subjectadverse effectsen
dc.subjectgrowthen
dc.titleCorticosteroids (inhaled and/or intranasal) in the treatment of respiratory allergy in children: safety vs. efficacyen
dc.typeResenha
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationUniv Fed Sao Paulo, Escola Paulista Med, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Escola Paulista Med, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil
dc.identifier.doi10.1157/13110315
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000254250800007


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record